Central nervous system lymphoma and its significance]

Wen Zheng,Ning-jing Lin,Yan Xie,Xiao-pei Wang,Mei-feng Tu,Wei-ping Liu,Yu-qin Song,Ling-yan Ping,Zhi-tao Ying,Li-juan Deng,Chen Zhang,Jun Zhu
DOI: https://doi.org/10.3760/cma.j.issn.0376-2491.2011.22.012
2011-01-01
Abstract:To explore the clinical features, diagnosis, treatment and prognosis of central nervous system lymphoma (CNSL).Retrospective analysis was conducted for 31 CNSL cases from January 2007 to December 2009 in our hospital. Their clinical data were analyzed by statistical software package SPSS 16.0.Accounting for around 4.7% of all lymphomas at our institution, the present cohort had 21 males and 10 females with a median age of 38 years old. The major clinical manifestations were focal neurological deficits associated with the site of disease or increased intracranial pressure. Most patients were treated with chemotherapy-based regimens. The overall response rate was 67.7% (21/31) with 32.3% (10/31) complete remission rate (CR) and 35.5% (11/31) partial remission rate (PR). Involvement outside CNS or bone marrow, high international prognostic index (IPI) and B symptoms had significant effects on the therapeutic efficacy (P < 0.05). The overall survival rates were 80.7%, 74.2%, 64.5% and 58.1% at 3, 6, 12, 24 months respectively. The median survival time was 22.5 months. Univariate analysis showed that the clinical efficacy had significant effects on the overall survival of patients (OR = 0.030, 95%CI: 0.003 - 0.270, P = 0.000).The prognosis of CNSL remains poor. New diagnostic tools and treatment modality need to be explored.
What problem does this paper attempt to address?